ALK and non-small cell lung carcinoma: While adjuvant osimertinib and alectinib are now the standard-of-care (SOC) for resected early-stage EGFR- and ALK-positive NSCLC, respectively, targeted therapies are under investigation in clinical trials to expand their use in the perioperative setting, aiming to replicate their success in mNSCLC.